Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuropsychological characterization of aggression in children and adolescents with conduct disorder or oppositional defiant disorder
2015-001916-37Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of risperidone, aripiprazole, atomoxetine and methylphenidate in conduct disorder (CD) and oppositional defiant disorder (ODD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Neuropsychological task performance. Started Sep 2021; status: completed.
02
Drugs
risperidonearipiprazoleatomoxetinemethylphenidate
03
Conditions
conduct disorder (CD)oppositional defiant disorder (ODD)
Beyond the preview
Go deeper on 2015-001916-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001916-37.